How To Reach C&ENACS Membership Number


 

June 3, 2002
Volume 80, Number 22
CENEAR 80 22 pp. 22-26
ISSN 0009-2347


SERONO AT A GLANCE
Headquarters: Geneva, Switzerland
Sales: $1.3 billiona
R&D expenditures: $309 million
Net income: $317 million
Employees: 4,600
Major products: Gonal-F (follitropin alfa) for infertility ($410 million); Rebif (interferon-beta 1a) for relapsing remitting multiple sclerosis ($380 million); Serostim and Saizen (somatropin) for treatment of HIV-associated wasting and growth retardation, respectively ($233 million total). 82% of all products are made by recombinant technology.
Website: http://www.serono.com
a Financial data are for 2001.
Page: 1 | 2 | 3 | Previous Page



Top


Chemical & Engineering News
Copyright © 2002 American Chemical Society



 
Go to
SERONO SETS SAIL
CEO Ernesto Bertarelli is confident the Swiss biotechnology firm is well-positioned for international industry leadership

RESEARCH
Serono Researchers Expect The Unexpected

SERONO AT A GLANCE

Related Stories
MIXED BAG FOR BIOPHARMA FIRMS
[C&EN, May 20, 2002]

Pharmaceutical Business
[C&EN, Jan. 28, 2002]

PCR FOR PRIONS
[C&EN, Jun. 18, 2001]

Related Company
E-mail this article to a friend
Print this article
E-mail the editor
 

Home | Table of Contents | Today's Headlines | Business | Government & Policy | Science & Technology | C&EN Classifieds
About C&EN | How To Reach Us | How to Advertise | Editorial Calendar | Email Webmaster

Chemical & Engineering News
Copyright © 2002 American Chemical Society. All rights reserved.
• (202) 872-4600 • (800) 227-5558

CASChemPortChemCenterPubs Page